Literature DB >> 18366307

Cerebrospinal fluid: identification of diagnostic markers for schizophrenia.

Emanuel Schwarz1, Sabine Bahn.   

Abstract

Schizophrenia is a complex neuropsychiatric disease but, despite extensive research efforts over the last 100 years, the etiology of this disorder remains elusive. Diagnosis is still based on a subjective, interview-based process, which may not align with the biological underpinnings of the symptoms. This old-fashioned descriptive approach contributes to the low treatment success and impedes early intervention, which is thought to be crucial for successful therapy. Therefore, there is an urgent need to discover biochemical analytes that facilitate an objective and reliable diagnosis. Disease markers might also have utility for tracking treatment success and compliance, as well as the discovery of novel drug targets. For schizophrenia and psychiatric disorders at large, analyzing cerebrospinal fluid (CSF) is an intuitive choice due to its close proximity to the brain and its clinical accessibility in the living patient. Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application. Here, we review molecular alterations of proteins and metabolites that have been identified in schizophrenia CSF and discuss their potential applicability as diagnostic markers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18366307     DOI: 10.1586/14737159.8.2.209

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  8 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

2.  Total protein is an effective loading control for cerebrospinal fluid western blots.

Authors:  Mahlon A Collins; Jiyan An; Danielle Peller; Robert Bowser
Journal:  J Neurosci Methods       Date:  2015-05-22       Impact factor: 2.390

3.  Disease and genetic contributions toward local tissue volume disturbances in schizophrenia: a tensor-based morphometry study.

Authors:  Yaling Yang; Keith H Nuechterlein; Owen R Phillips; Boris Gutman; Florian Kurth; Ivo Dinov; Paul M Thompson; Robert F Asarnow; Arthur W Toga; Katherine L Narr
Journal:  Hum Brain Mapp       Date:  2012-09       Impact factor: 5.038

4.  Neurobehavioral deficits in db/db diabetic mice.

Authors:  Ajaykumar N Sharma; Khalid M Elased; Teresa L Garrett; James B Lucot
Journal:  Physiol Behav       Date:  2010-07-14

5.  Revisiting thyroid hormones in schizophrenia.

Authors:  Nadine Correia Santos; Patrício Costa; Dina Ruano; António Macedo; Maria João Soares; José Valente; Ana Telma Pereira; Maria Helena Azevedo; Joana Almeida Palha
Journal:  J Thyroid Res       Date:  2012-03-26

6.  Plasma BDNF levels vary in relation to body weight in females.

Authors:  Anilkumar Pillai; Davide Bruno; Antero S Sarreal; Raymundo T Hernando; Leslie A Saint-Louis; Jay Nierenberg; Stephen D Ginsberg; Nunzio Pomara; Pankaj D Mehta; Henrik Zetterberg; Kaj Blennow; Peter F Buckley
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

7.  The correlation between plasma brain-derived neurotrophic factor and cognitive function in bipolar disorder is modulated by the BDNF Val66Met polymorphism.

Authors:  Sheng-Yu Lee; Tzu-Yun Wang; Shiou-Lan Chen; Yun-Hsuan Chang; Po-See Chen; San-Yuan Huang; Nian-Sheng Tzeng; Liang-Jen Wang; I Hui Lee; Kao Chin Chen; Yen Kuang Yang; Yi-Hsin Yang; Ru-Band Lu; Cheng-Sheng Chen
Journal:  Sci Rep       Date:  2016-12-01       Impact factor: 4.379

8.  Microscopic particles in two fractions of fresh cerebrospinal fluid in twins with schizophrenia or bipolar disorder and in healthy controls.

Authors:  Viktoria Johansson; Rolf Nybom; Lennart Wetterberg; Christina M Hultman; Tyrone D Cannon; Anette G M Johansson; Carl Johan Ekman; Mikael Landén
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.